LDS/Medical Tests/JAK2 Gene Mutation (Exons 12-15 or full sequencing) Analysis

JAK2 Gene Mutation (Exons 12-15 or full sequencing) Analysis

The JAK-2 mutation analysis assay is designed to detect and quantify the point mutation V617F in the (JAK-2) gene. This gene encodes for a cytoplasmic tyrosine kinase also known as Janus Tyrosine Kinase 2. The mutation changes the encoded amino acid valine at position 617 to phenylalanine, altering this highly conserved valine in the negative regulatory JH2 domain. This has the effect of dysregulating the kinase activity. This mutation leads to constitutive activation of the kinase and is found in myeloproliferative disorders (MPD) such as essential thrombocythemia (ET), idiopathic myelofibrosis (IMF), and polycythemia vera (PV).

As new therapies are developed for IMF, ET, and PV, there is a need for quantitative techniques to follow the level of the tumor clone because neoplastic cells in these disorders are not readily distinguishable from normal hematopoietic cells. The single acquired mutation of JAK2 is present in more than half of patients with myeloproliferative disorders (other than chronic myeloid leukemia). The frequency of the V617F mutation is reported as 74-97% in polycythemia vera, 33-57% in essential thrombocythemia, and 35-57% in chronic idiopathic myelofibrosis. A positive result strongly supports a diagnosis of PV, ET, or IMF. It is particularly useful for establishing a diagnosis of PV in patients with marked erythrocytosis with a hemoglobin >18 g/dL in males or >16 g/dL in females. A negative result does not rule out the possibility of PV, ET, or IMF.

  • Diagnosis of myeloproliferative disorders (MPD) such as polycythemia vera, essential thrombocythemia, and chronic idiopathic myelofibrosis
  • To monitor clinical outcome and therapy treatment
  • To help distinguish MPD from various reactive or fibrotic marrow conditions
  • To differentiate JAK2-positive MPD from JAK2-negative MPD

Positive in:

  • Polycythemia vera (75-97%)
  • Essential Thrombocythemia (35-57%)
  • Chronic Idiopathic Myelofibrosis (35-57%)
  • Other myeloid neoplasms

The JAK2 V617F mutation has been reported in 65% - 97% of polycythemia vera (PV) cases, and in 25% - 60% of patients with essential thrombocythemia (ET) and idiopathic myelofibrosis (IMF). The percentage of JAK2 mutant allele is related to both the extent of dominance of the JAK2 positive clone, and also the clone’s genotype. A mutant allele % of >50 indicates homozygosity for the JAK2 V617F mutation, and is reported in many patients with PV or IMF, but not in ET. Quantitation of the JAK2 V617F mutation is important in monitoring the malignant clone and assessing response to therapy. Final interpretation requires correlation with other clinical and hematologic findings.

A negative result does not rule out the diagnosis of PV, ET, or MF. When monitoring disease, a decrease in JAK2 V617F concentration suggests therapeutic response; an increase suggests relapse.

Mutation Not Detected
 

 

 

Real-Time PCR, amplification refractory mutation system (ARMS)

Whole Blood EDTA (Lavender) or Heparin (Green). 

Stability

  • Ambient: 1-3 days
  • Refrigerated: 3-5 days
  • Frozen: 30 days

CBC with Differential, Bone Marrow Biopsy Morphology, Bone Marrow Flow Cytometry and Cytogenetics, Erythropoietin, Possible Peripheral Blood Cytogenetics and Flow Cytometry if Marrow is not available.

1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login